메조포러스실리카를 이용한 페북소스타트 고체분산체 개발

• 영문명: Development of Febuxostat Solid Dispersion using a Mesoporous Silica
• 발행기관: 대한약학회
• 저자명: 신윤환(Yoon Hwan Shin) 권순형(Soon Hyung Kwon) 최진석(Jin-Seok Choi)
• 간행물 정보: 『약학회지』제68권 제5호(2024년), 378~384쪽, 전체 7쪽
• 주제분류: 의약학 > 기타의약학
• 파일형태: PDF
• 발행일자: 2024.10.31

국문 초록

Mesoporous silica (MCM-41) can encapsulate drugs, prevent drug recrystallization, and improve dispersibility. MCM-41, a carrier with many advantages, can be applied for febuxostat solubilzation. The purpose of this study is to develop a febuxostat solid dispersion (SD) containing MCM-41 and Kollidon® (K12) to improve the dissolution rate and ensure stability. The SD preparation method was a solvent evaporation. The final formulation (SD1, febuxostat :MCM-41 : Kollidon®(K12)=1:5:2 [w/w]) was successfully developed. The melting point and crystallinity of febuxostat in the SD1 formulation have changed, and drug-excipient interactions were also confirmed. Based on these results, it is believed that the dissolution rate was improved by 6.2- (pH 1.2 media), 2.1- (distilled water), and 1.1-fold (pH 6.8 buffer) compared to the commercial product. In conclusion, the febuxostat-SD through a ternary system was successfully developed, which is believed to be due to the physicochemical changes in the SD1 formulation.

목차

서 론(Introduction)

방 법(Methods)

결과 및 고찰(Results and Discussion)

결 론(Conclusion)

감사의말씀(Acknowledgment)

Conflict of Interest

References

키워드

Febuxostat Solid dispersion Solvent evaporation method Solubilization Dissolution MCM-41